1. Home
  2. RL vs BIIB Comparison

RL vs BIIB Comparison

Compare RL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ralph Lauren Corporation

RL

Ralph Lauren Corporation

HOLD

Current Price

$366.87

Market Cap

22.1B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.61

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RL
BIIB
Founded
1967
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1B
24.2B
IPO Year
1997
1991

Fundamental Metrics

Financial Performance
Metric
RL
BIIB
Price
$366.87
$181.61
Analyst Decision
Strong Buy
Buy
Analyst Count
14
23
Target Price
$360.29
$176.48
AVG Volume (30 Days)
617.9K
1.9M
Earning Date
11-06-2025
10-30-2025
Dividend Yield
0.99%
N/A
EPS Growth
28.75
N/A
EPS
13.54
10.97
Revenue
$7,570,600,000.00
$10,065,900,000.00
Revenue This Year
$12.88
$3.61
Revenue Next Year
$4.97
N/A
P/E Ratio
$27.22
$16.52
Revenue Growth
12.32
4.77
52 Week Low
$176.61
$110.04
52 Week High
$374.00
$185.17

Technical Indicators

Market Signals
Indicator
RL
BIIB
Relative Strength Index (RSI) 65.98 72.92
Support Level $349.40 $174.53
Resistance Level $374.00 $182.94
Average True Range (ATR) 10.51 5.22
MACD 1.58 0.25
Stochastic Oscillator 89.52 83.54

Price Performance

Historical Comparison
RL
BIIB

About RL Ralph Lauren Corporation

Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: